Primary regulatory
Tesamorelin Clinical Trial Registry Entries: ClinicalTrials.gov
ClinicalTrials.gov registry entries for tesamorelin clinical trials, including the pivotal Phase 3 trials for HIV-associated lipodystrophy that supported FDA approval of Egrifta.
ClinicalTrials.gov / U.S. National Library of MedicinePublished Jan 1, 2010Accessed Jul 1, 2026
Registry record
Source metadata
- Publisher
- ClinicalTrials.gov / U.S. National Library of Medicine
- Source type
- Primary regulatory
- Registry ID
clinicaltrials-gov-tesamorelin
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.